CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Mulungu +1 moredrug
Likely dose
Mulungu 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01948622
NCT01948622Phase 2Completed
CompareCT.gov

Anxiety Control by Using Erythrina Mulungu in Mandibular Third Molars Extraction

Liane Maciel de Almeida Souza·interventional·Posted Sep 23, 2013·Updated Sep 23, 2013

In Brief

A Phase 2 clinical trial evaluating Mulungu and Placebo for Dental Anxiety and Impacted Third Molar Tooth. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study evaluated the effectiveness of the Erythrina mulungu in controlling anxiety in patients undergoing bilateral extraction of asymptomatic, impacted mandibular third molars.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDental Anxiety, Impacted Third Molar Tooth
CountriesBrazil
CollaboratorsUniversity of Campinas, Brazil

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2013
Enrollment StartJan 1, 2012
Primary CompletionJun 1, 2012
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.8 years ago

Interventions

Mulungudrug

500 mg/single dose/1 hour before dental surgery

Placebodrug

500 mg/single dose/1 hour before dental surgery